Carmustine

Alkylating Drug — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Carmustine is an ofp drug in the Alkylating Drug class catalogued in DrugCentral. It was first approved by the FDA in 1977. Its mechanism of action is classified as Alkylating Activity. DrugCentral lists 1 molecular target, including GSR. Recorded indications include Diffuse non-Hodgkin's lymphoma, large cell, Glioblastoma multiforme of brain, Glioma, malignant and Hodgkin's disease.

• Approval status: ofp (first approved 1977 by the FDA).
• Drug class: Alkylating Drug.
• Mechanism of action: Alkylating Activity.
• Molecular targets: GSR (1 listed in DrugCentral).
• Indications: Diffuse non-Hodgkin's lymphoma, large cell, Glioblastoma multiforme of brain, Glioma, malignant, Hodgkin's disease and Malignant neoplasm of brain and others.
• ATC code: L01AD01 (Nitrosoureas).
• Molecular formula: C5H9Cl2N3O2; molecular weight 214.05 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Diffuse non-Hodgkin's lymphoma, large cell
• Glioblastoma multiforme of brain
• Glioma, malignant
• Hodgkin's disease
• Malignant neoplasm of brain
• Multiple myeloma
• Non-Hodgkin's lymphoma

Off-label uses (3)

• Allogeneic bone marrow transplantation
• Astrocytoma, anaplastic
• Mycosis fungoides

Contraindications (25)

• Abscess of brain
• Acute leukemia, disease
• Anemia
• Bacterial infectious disease
• Bone marrow depression
• Breastfeeding (mother)
• Cerebral edema
• Disease of liver
• Disorder of lung
• Epilepsy
• Fibrosis of lung
• Infectious disease
• Kidney disease
• Leukopenia
• Liver function tests abnormal
• Meningitis
• Mycosis
• Obstructive hydrocephalus
• Pregnancy, function
• Protozoal Infection
• Pulmonary Infiltrates
• Retinal hemorrhage
• Significant Bleeding
• Thrombocytopenic disorder
• Viral disease

Mechanism & targets

• Mechanism of action (MoA): Alkylating Activity
• Established pharmacologic class: Alkylating Drug

Molecular targets (1)

Target	Gene	Action	Activity
Glutathione reductase, mitochondrial	GSR	inhibitor	IC50 5.09

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1977-03-07	FDA	—	EMCURE PHARMS LTD

ATC classification

ATC code	Therapeutic hierarchy
L01AD01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrosoureas

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelodysplastic syndrome	983.3
Febrile neutropenia	570.5
Acute myeloid leukaemia	514.4
Malignant transformation	442.9
Mucosal inflammation	419.4
Second primary malignancy	391.1
Disease progression	311.7
Haematotoxicity	307.1
Venoocclusive liver disease	301.5
Brain oedema	298.5
Thrombocytopenia	207.9
Pneumocephalus	175.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Carmustine is on its molecule page.

• Molecular formula: C₅H₉Cl₂N₃O₂
• Molecular weight: 214.05 g/mol
• CAS number: —
• InChIKey: DLGOEMSEDOSKAD-UHFFFAOYSA-N
• PubChem CID: 2578

ClCCNC(=O)N(CCCl)N=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Carmustine used for?

DrugCentral lists the following indications for Carmustine: Diffuse non-Hodgkin's lymphoma, large cell, Glioblastoma multiforme of brain, Glioma, malignant, Hodgkin's disease, Malignant neoplasm of brain, Multiple myeloma and Non-Hodgkin's lymphoma.

How does Carmustine work?

Carmustine is classified as Alkylating Activity; its molecular targets in DrugCentral include GSR (inhibitor).

When was Carmustine first approved?

Carmustine was first approved by the FDA in 1977.

What drug class does Carmustine belong to?

Carmustine is in the Alkylating Drug class.

What is the chemical formula of Carmustine?

Carmustine has the molecular formula C5H9Cl2N3O2 and a molecular weight of 214.05 g/mol.

Sources

• DrugCentral drug card 512 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL513 — compound record and bioactivity
• PubChem CID 2578 — chemical identifiers
• DrugBank DB00262 — drug record
• FDA UNII U68WG3173Y — substance identity
• DailyMed: FDA labels for Carmustine — current prescribing information (label search)
• UniProt P00390 (GSR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.